Brickell Biotech, Inc. (BBI): Price and Financial Metrics

Brickell Biotech, Inc. (BBI): $0.55

0.00 (-0.71%)

POWR Rating

Component Grades













Add BBI to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • BBI scores best on the Sentiment dimension, with a Sentiment rank ahead of 65.52% of US stocks.
  • The strongest trend for BBI is in Value, which has been heading down over the past 52 weeks.
  • BBI's current lowest rank is in the Quality metric (where it is better than 9.32% of US stocks).

BBI Stock Summary

  • With a price/sales ratio of 139.96, Brickell Biotech Inc has a higher such ratio than 97.4% of stocks in our set.
  • With a year-over-year growth in debt of -92.31%, Brickell Biotech Inc's debt growth rate surpasses merely 2.38% of about US stocks.
  • As for revenue growth, note that BBI's revenue has grown -90.39% over the past 12 months; that beats the revenue growth of just 1.39% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Brickell Biotech Inc, a group of peers worth examining would be COCP, OMER, INS, LIFE, and GSIT.
  • BBI's SEC filings can be seen here. And to visit Brickell Biotech Inc's official web site, go to

BBI Valuation Summary

  • BBI's price/earnings ratio is -2; this is 105.48% lower than that of the median Healthcare stock.
  • Over the past 243 months, BBI's EV/EBIT ratio has gone up 17.3.
  • BBI's price/sales ratio has moved up 161 over the prior 243 months.

Below are key valuation metrics over time for BBI.

Stock Date P/S P/B P/E EV/EBIT
BBI 2021-08-31 188.4 2.8 -2.0 -1.2
BBI 2021-08-30 175.1 2.6 -1.9 -1.1
BBI 2021-08-27 178.3 2.7 -1.9 -1.1
BBI 2021-08-26 181.0 2.7 -1.9 -1.2
BBI 2021-08-25 181.0 2.7 -1.9 -1.2
BBI 2021-08-24 169.4 2.6 -1.8 -1.0

BBI Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at -22.3%.
  • Its 3 year revenue growth rate is now at -95.6%.
  • Its 3 year net cashflow from operations growth rate is now at -160.09%.
Over the past 67 months, BBI's revenue has gone down $20,613,000.

The table below shows BBI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.337 -28.949 -31.845
2021-03-31 0.793 -19.315 -25.815
2020-12-31 1.822 -20.034 -20.913
2020-09-30 2.464 -29.324 -24.41
2020-06-30 3.505 -37.763 -24.947
2020-03-31 2.898 -37.419 -22.258

BBI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BBI has a Quality Grade of D, ranking ahead of 9.32% of graded US stocks.
  • BBI's asset turnover comes in at 0.011 -- ranking 388th of 681 Pharmaceutical Products stocks.
  • AMPH, VTVT, and IONS are the stocks whose asset turnover ratios are most correlated with BBI.

The table below shows BBI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 12.593
2021-03-31 0.025 1 11.420
2020-12-31 0.073 1 15.834
2020-09-30 0.116 1 40.527
2020-06-30 0.156 1 -6.335
2020-03-31 0.110 1 -1.800

BBI Price Target

For more insight on analysts targets of BBI, see our BBI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.50 Average Broker Recommendation 1.25 (Strong Buy)

BBI Stock Price Chart Interactive Chart >

Price chart for BBI

BBI Price/Volume Stats

Current price $0.55 52-week high $1.70
Prev. close $0.55 52-week low $0.47
Day low $0.54 Volume 700,500
Day high $0.56 Avg. volume 2,032,899
50-day MA $0.69 Dividend yield N/A
200-day MA $0.92 Market Cap 47.17M

Brickell Biotech, Inc. (BBI) Company Bio

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

BBI Latest News Stream

Event/Time News Detail
Loading, please wait...

BBI Latest Social Stream

Loading social stream, please wait...

View Full BBI Social Stream

Latest BBI News From Around the Web

Below are the latest news stories about Brickell Biotech Inc that investors may wish to consider to help them evaluate BBI as an investment opportunity.

Hyperhidrosis Treatment Market - Understand the Growth Trajectory and Rising Figures, Key Players - Allergan (Ireland), Brickell Biotech, Inc. (U.S.), Dermira, Inc. (U.S.), GlaxoSmithKline plc (U.K.),

The Hyperhidrosis Treatment Market is expected to grow at a CAGR of xx% and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2021 The industry research Hyperhidrosis Treatment Market report published by DECISIVE MARKETS INSIGHTS

OpenPR | October 13, 2021

Brickell plans to submit new drug application to FDA for gel

On the heels of a recently completed phase three clinical trial, Brickell Biotech Inc. (Nasdaq: BBI) plans to submit a new drug application to the U.S. Food and Drug Administration next year for its sofpironium bromide gel, which could treat excessive underarm sweating.

Colorado Daily | October 7, 2021

Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating

Brickell Biotech Inc (NASDAQ: BBI ) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel for primary axillary hyperhidrosis (excessive underarm sweating). The Company plans to file an FDA marketing application in mid-2022. In Cardigan I trial (n=350), the proportion of subjects achieving at least a … Full story available on

Benzinga | October 7, 2021

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Sofpironium bromide gel, 15% was generally well-tolerated

Intrado Digital Media | October 7, 2021

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to host a key opinion leader (KOL) webinar on DYRK1A (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A), which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT.

Intrado Digital Media | September 17, 2021

Read More 'BBI' Stories Here

BBI Price Returns

1-mo -24.66%
3-mo -14.58%
6-mo -40.89%
1-year -23.62%
3-year -93.51%
5-year -97.30%
YTD -29.53%
2020 -47.97%
2019 -81.84%
2018 -35.52%
2017 -20.43%
2016 -43.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9043 seconds.